

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6834467

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	SECURITY INTEREST	
CONVEYING PARTY DATA		
	Name	Execution Date
	ANUTRA MEDICAL, INC.	07/27/2021
RECEIVING PARTY DATA		
Name:	VENTURE LENDING & LEASING IX, INC.	
Street Address:	104 LA MESA DRIVE, SUITE 102	
City:	PORTOLA VALLEY	
State/Country:	CALIFORNIA	
Postal Code:	94028	
PROPERTY NUMBERS Total: 8		
Property Type	Number	
Patent Number:	9387151	
Patent Number:	D774182	
Patent Number:	9393177	
Patent Number:	D763433	
Patent Number:	9579257	
Patent Number:	D750768	
Application Number:	10010482	
Application Number:	10010483	
CORRESPONDENCE DATA		
Fax Number:	(415)777-4961	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	4159811400	
Email:	nsust@foxrothschild.com	
Correspondent Name:	JEFF KLUGMAN	
Address Line 1:	1 FRONT STREET SUITE 3200	
Address Line 4:	SAN FRANCISCO, CALIFORNIA 94111	
ATTORNEY DOCKET NUMBER:	325086-02111	
NAME OF SUBMITTER:	JEFFREY T. KLUGMAN	
SIGNATURE:	/Jeffrey T. Klugman/	

DATE SIGNED:	07/27/2021
--------------	------------

Total Attachments: 9

source=Intellectual Property Security Agreement - Anutra Medical #4#page1.tif
source=Intellectual Property Security Agreement - Anutra Medical #4#page2.tif
source=Intellectual Property Security Agreement - Anutra Medical #4#page3.tif
source=Intellectual Property Security Agreement - Anutra Medical #4#page4.tif
source=Intellectual Property Security Agreement - Anutra Medical #4#page5.tif
source=Intellectual Property Security Agreement - Anutra Medical #4#page6.tif
source=Intellectual Property Security Agreement - Anutra Medical #4#page7.tif
source=Intellectual Property Security Agreement - Anutra Medical #4#page8.tif
source=Intellectual Property Security Agreement - Anutra Medical #4#page9.tif

INTELLECTUAL PROPERTY SECURITY AGREEMENT

This Intellectual Property Security Agreement (this "Agreement") is made as of July 27, 2021, by and between ANUTRA MEDICAL, INC., a Delaware corporation ("Grantor"), and VENTURE LENDING & LEASING IX, INC., a Maryland corporation ("Secured Party").

RECITALS

A. Pursuant to that certain Loan and Security Agreement of even date herewith between Grantor, as borrower, and Secured Party, as lender (as modified by the Supplement thereto of even date herewith and, as such agreement may from time to time be amended, restated, modified or otherwise supplemented) (the "Loan Agreement"), Secured Party has agreed to make certain advances of money and to extend certain financial accommodations to Grantor (the "Loans") in the amounts and manner set forth in the Loan Agreement. All capitalized terms used herein without definition shall have the meanings ascribed to them in the Loan Agreement.

B. Secured Party is willing to make the Loans to Grantor, but only upon the condition, among others, that Grantor shall grant to Secured Party a security interest in substantially all of Grantor's personal property whether presently existing or hereafter acquired. To that end, Grantor has executed in favor of Secured Party the Loan Agreement granting a security interest in all Collateral, and is executing this Agreement with respect to certain items of Intellectual Property, in particular.

NOW, THEREFORE, THE PARTIES HERETO AGREE AS FOLLOWS:

1. Grant of Security Interest. As collateral security for the prompt and complete payment and performance of all of Grantor's present or future Obligations, Grantor hereby grants a security interest and mortgage to Secured Party, as security, in and to Grantor's entire right, title and interest in, to and under the following Intellectual Property, now owned or hereafter acquired by Grantor or in which Grantor now holds or hereafter acquires any interest (all of which shall collectively be called the "IP Collateral"):

(a) Any and all copyrights, whether registered or unregistered, held pursuant to the laws of the United States, any State thereof or of any other country; all registrations, applications and recordings in the United States Copyright Office or in any similar office or agency of the United States, and State thereof or any other country; all continuations, renewals, or extensions thereof; and any registrations to be issued under any pending applications, including without limitation those set forth on Exhibit A attached hereto (collectively, the "Copyrights");

(b) All letters patent of, or rights corresponding thereto in, the United States or any other country, all registrations and recordings thereof, and all applications for letters patent of, or rights corresponding thereto in, the United States or any other country, including, without limitation, registrations, recordings and applications in the United States Patent and Trademark Office or in any similar office or agency of the United States, any State thereof or any other country; all reissues, continuations, continuations-in-part or extensions thereof; all petty patents, divisionals, and patents of addition; and all patents to be issued under any such applications, including without limitation the patents and patent applications set forth on Exhibit B attached hereto (collectively, the "Patents");

(c) All trademarks, trade names, corporate names, business names, trade styles, service marks, logos, other source or business identifiers, prints and labels on which any of the foregoing have appeared or appear, designs and general intangibles of like nature, now existing or hereafter adopted or acquired, all registrations and recordings thereof, and any applications in connection therewith, including, without limitation, registrations, recordings and applications in the United States Patent and Trademark Office or in any similar office or agency of the United States, any State thereof or any other country or any political subdivision thereof, and reissues, extensions or

renewals thereof, and the entire goodwill of the business of Grantor connected with and symbolized by such trademarks, including without limitation those set forth on Exhibit C attached hereto (collectively, the “Trademarks”);

(d) Any and all claims for damages by way of past, present and future infringement of any of the rights included above, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified above;

(e) All licenses or other rights to use any of the Copyrights, Patents or Trademarks, and all license fees and royalties arising from such use to the extent permitted by such license or rights;

(f) All amendments, renewals and extensions of any of the Copyrights, Trademarks or Patents;
and

(g) All proceeds and products of the foregoing, including without limitation all payments under insurance or any indemnity or warranty payable in respect of any of the foregoing.

Notwithstanding the foregoing the term “IP Collateral” shall not include: (a) “intent-to-use” trademarks at all times prior to the first use thereof, whether by the actual use thereof in commerce, the recording of a statement of use with the United States Patent and Trademark Office or otherwise, but only to the extent the granting of a security interest in such “intent to use” trademarks would be contrary to applicable law or (b) any contract, instrument or chattel paper in which Grantor has any right, title or interest if and to the extent such contract, instrument or chattel paper includes a provision containing a restriction on assignment such that the creation of a security interest in the right, title or interest of Grantor therein would be prohibited and would, in and of itself, cause or result in a default thereunder enabling another person party to such contract, instrument or chattel paper to enforce any remedy with respect thereto; provided, however, that the foregoing exclusion shall not apply if (i) such prohibition has been waived or such other person has otherwise consented to the creation hereunder of a security interest in such contract, instrument or chattel paper, or (ii) such prohibition would be rendered ineffective pursuant to Sections 9-407(a) or 9-408(a) of the UCC, as applicable and as then in effect in any relevant jurisdiction, or any other applicable law (including the Bankruptcy Code or principles of equity); provided further that immediately upon the ineffectiveness, lapse or termination of any such provision, the term “Collateral” shall include, and Grantor shall be deemed to have granted a security interest in, all its rights, title and interests in and to such contract, instrument or chattel paper as if such provision had never been in effect; and provided further that the foregoing exclusion shall in no way be construed so as to limit, impair or otherwise affect Secured Party’s unconditional continuing security interest in and to all rights, title and interests of Grantor in or to any payment obligations or other rights to receive monies due or to become due under any such contract, instrument or chattel paper and in any such monies and other proceeds of such contract, instrument or chattel paper.

2. Covenants and Warranties. Grantor represents, warrants, covenants and agrees as follows:

(a) Grantor is now the sole owner of the IP Collateral, except for Permitted Liens;

(b) During the term of this Agreement, Grantor will not transfer or otherwise encumber any interest in the IP Collateral, except as permitted under the Loan Agreement, including without limitation, Sections 6.2 and 6.5 thereof;

(c) To its knowledge, each of the Patents is valid and enforceable, and no part of the IP Collateral has been judged invalid or unenforceable, in whole or in part, and, to its knowledge, no claim has been made that any part of the IP Collateral violates the rights of any third party;

(d) **Grantor shall deliver to Secured Party within thirty (30) days of the last day of each fiscal quarter, a report signed by an officer of Grantor, in form reasonably acceptable to Secured Party, listing any applications or registrations that Grantor has made or filed in respect of any Patents, Copyrights or**

Trademarks since the prior such report delivered to Secured Party and the status of any outstanding applications or registrations. Grantor shall advise Secured Party of any material change in the composition of the IP Collateral that is not otherwise described in any quarterly report delivered under this Section 2(d), including but not limited to any subsequent ownership right of the Grantor in or to any Trademark, Patent or Copyright not set forth in Exhibits A, B, or C, as soon as commercially practicable after the occurrence of such material change;

(e) Grantor shall use reasonable commercial efforts to (i) protect, defend and maintain the validity and enforceability of the Trademarks, Patents and Copyrights material to Grantor's business, (ii) detect infringements of the Trademarks, Patents and Copyrights and advise Secured Party as soon as commercially practicable in writing of material infringements detected and (iii) not allow any material Trademarks, Patents or Copyrights to be abandoned, forfeited or dedicated to the public without the written consent of Secured Party, which consent shall not be unreasonably withheld;

(f) To the extent not already registered, Grantor shall apply for registration with the United States Patent and Trademark Office or the United States Copyright Office, as applicable: (i) those intellectual property rights listed on Exhibits A, B and C hereto within thirty (30) days of the date of this Agreement; and (ii) those additional intellectual property rights developed or acquired by Grantor from time to time in connection with any product or service, prior to the sale or licensing of such product or the rendering of such service to any third party (including without limitation revisions or additions to the intellectual property rights listed on such Exhibits A, B and C), except with respect to such rights that Grantor determines in its sole but reasonable commercial judgment need not be registered to protect its own business interests. In the case of Copyrights to be registered with the United States Copyright Office, Grantor will register such Copyrights on an expedited basis; and

(g) Grantor shall not enter into any agreement that would materially impair or conflict with Grantor's obligations hereunder without Secured Party's prior written consent, which consent shall not be unreasonably withheld. Grantor shall not permit the inclusion in any material contract to which it becomes a party of any provisions that could or might in any way prevent the creation of a security interest in Grantor's rights and interests in any property included within the definition of the Collateral acquired under such contracts.

3. Further Assurances; Attorney in Fact.

(a) Grantor will make, execute, acknowledge and deliver, and file and record in the proper filing and recording places in the United States, all instruments, including appropriate financing and continuation statements and collateral agreements and filings with the United States Patent and Trademark Office and the Register of Copyrights, and take all such action as may be reasonably requested by Secured Party, to perfect Secured Party's security interest in all Copyrights, Patents and Trademarks and otherwise to carry out the intent and purposes of this Agreement, or for assuring and confirming to Secured Party the grant or perfection of a security interest in all IP Collateral.

(b) Grantor hereby irrevocably appoints Secured Party as Grantor's attorney-in-fact, with full authority in the place and stead of Grantor and in the name of Grantor, from time to time in Secured Party's discretion, to take any action and to execute any instrument which Secured Party may deem necessary or advisable to accomplish the purposes of this Agreement, including (i) to modify, in its sole discretion, Exhibits A, B and C of this Agreement, as appropriate, without first obtaining Grantor's approval of or signature to such modification, to include reference to any right, title or interest in any Copyrights, Patents or Trademarks acquired by Grantor after the execution hereof or to delete any reference to any right, title or interest in any Copyrights, Patents or Trademarks in which Grantor no longer has or claims any right, title or interest, (ii) to file, in its sole discretion, one or more financing or continuation statements and amendments thereto, relative to any of the IP Collateral without the signature of Grantor where permitted by law, and (iii) after the occurrence, and during the continuance, of an Event of Default, to transfer the IP Collateral into the name of Secured Party or a third party to the extent permitted under the Loan Agreement and the California Uniform Commercial Code.

4. Events of Default. The occurrence of any of the following shall constitute an Event of Default under this Agreement:

(a) An Event of Default under the Loan Agreement; or

(b) Grantor breaches any warranty or agreement made by Grantor in this Agreement and, as to any breach that is capable of cure, Grantor fails to cure such breach within thirty (30) days of the sooner to occur of Grantor's receipt of notice of such breach from Secured Party or the date on which such breach first becomes known to Grantor.

5. Amendments. This Agreement may be amended only by a written instrument signed by both parties hereto, except for amendments permitted under Section 3 hereof to be made by Secured Party alone.

6. Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original but all of which together shall constitute the same instrument.

[Signature Pages Follow]

[Signature page to Intellectual Property Security Agreement]

IN WITNESS WHEREOF, the parties hereto have executed this Agreement on the day and year first above written.


Address of Grantor:

10404 Chapel Hill Rd
Suite 104
Morrisville, NC 27513
Attn: CEO

GRANTOR:

ANUTRA MEDICAL, INC.

By:



Name: Jeff Daner

Its:

Address of Secured Party:

104 La Mesa Dr., Suite 102
Portola Valley, CA 94028
Attn: Chief Financial Officer

SECURED PARTY:

VENTURE LENDING & LEASING IX, INC.

By:

Name:

Its:

[Signature page to Intellectual Property Security Agreement]

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above written.

GRANTOR:

Address of Grantor:

ANUTRA MEDICAL, INC.

1000 Perimeter Park Drive, Suite E
Morrisville, NC 27560
Attn:

By: _____

Name: _____

Its: _____

GRANTOR:

SECURED PARTY:

Address of Secured Party:

VENTURE LENDING & LEASING IX, INC.

104 La Mesa Drive, Suite 102
Portola Valley, CA 94028
Attn: Chief Financial Officer

By: Maurice Werdegan
Maurice Werdegan (RA 15, 2021 1748 PM)

Name: Maurice Werdegan

Its: Chief Executive Officer

EXHIBIT A

Copyrights

Description

Registration Number

Registration Date

None

EXHIBIT B

Patents

File Reference No.	Subject Matter	Patent Status	Commentary
4556-101	Syringe Fill System (utility)	U.S. Pat. No. 9,387,151 issued July 12, 2016	Utility patent covering the overall product
4556-101 CON	Syringe Fill System (utility)	U.S. Pat. No. 10,010,482 issued July 3, 2018	Utility patent covering the overall product
4556-101D	Syringe Fill System (design)	U.S. Design Pat. No. D774182 issued December 13, 2016	Design patent covering the overall product
4556-101 Canada	Syringe Fill System (utility)	Canadian Patent Application No. 2,920,835	Pending and undergoing examination
4556-101 Europe	Syringe Fill System (utility)	European Patent Application No. 3035903 issued August 22, 2018	European Patent validated in UK, France, Germany, and Italy
4556-102	Cassette Assembly (utility)	U.S. Pat. No. 9,393,177 issued July 19, 2016	Utility patent covering the cassette assembly
4556-102 CON	Cassette Assembly (utility)	U.S. Patent No. 10,010,483 issued July 3, 2018	Utility patent covering the cassette assembly
4556-102D	Cassette Assembly (design)	U.S. Design Patent No. D763,433 issued August 9, 2016	Design patent covering the cassette assembly
4556-103	Haptic Syringe (utility)	U.S. Patent No. 9,579,257 issued February 28, 2017	Utility patent covering the syringe
4556-103D	Haptic Syringe (design)	U.S. Design Patent No. D750,768 issued March 1, 2016	Design patent covering the syringe
4556-104 Europe	Design of Syringe Fill System, Cassette Assembly, and Haptic Syringe	European Community Design Registration Nos. 002590794-0001, 002590794-0002, and 002590794-0003 all issued December 4, 2014	Registration -001 (Syringe Fill System Design); Registration -002 (Cassette Assembly Design); Registration -003 (Haptic Syringe Design)

EXHIBIT C

Trademarks

<u>Description</u>	<u>U.S. Registration/Application Number</u>	<u>Registration/Application Date</u>
Anutra	86266896	April 30, 2014